for more information about stanelco click on the links.

driver's research page link
http://www.moneyam.com/InvestorsRoom/posts.php?tid=7681#lastread
website link
http://www.stanelco.co.uk/index.htm

Grow up child

Daz England - 20 Dec 2005 19:12 - 13861 of 13861
Grow up child
-------------

Masterful post full of intelligent obseRvation, mature cognisance of the company in question, in total control of his mind set, the DAZ Man is a genius , just breathtaking.
Mind you I think the fact thaT I was right about 14p today might balance his awesome rhetoric, but what do I know compared to such a giant of investment?.
I give you the thoughts of DAZ man, bubbles in the bath????

ROTFFLMFAO!!!!!!

Bosley - 7/8 months to go on the Asda deal, thanks for the info. I have sold my entire holding for just over 60% gain, looking to buy back at around 12p.

Ah yes the explosive one who threatened that selling below 30p would be fatal, what a bunch of losers.

Bling, if your going to quote me then at least get it right.... I also find it funny how you can call me a loser when your the one with nothing better to do than post shite remarks like that!!

It doesn't take long to decide whom to filter here, I have just filtered three shorters as they are posting nothing but tripe.

News is coming to save the SP from going lower, and it won't be so much a bear squeeze as a bear trap.

Childish. I wont be drawn in. Stop the abuse Blinger and grow up.

the boy can,t help IT /// IT S IN HIS MAKEUP SO TO SPEAK/////

explosive/bosley.

I had a look on FYB and they seem to have info that say the contract ends on the 6th of April with ASDA. Any thoughts?

Yep. T'was me who thinks 6 April 2006.

The Circular to Shareholders dated 5 August 2005 concerning Biotec says, in the section of Material Contracts, on page 43 :-

The Agreement with ASDA is dated 23 March 2005 between (1) the Company and (2) ASDA Stores Limited ("ASDA") (the ADSA Agreement"), whereby the Company grants ASDA certain exclusive rights in relation to its Greenseal tray lidding technology (the "Technology"), within the food sector within the UK and Ireland for a period of 12 months and 14 days from 23 March 2005 (the "ASDA Exclusivity Period").

That document to Shareholders contains a wealth of information that dispells many of the myths, scares, ramps, deramps and just plain incorrect points that get put about. It should be required reading by anyone wishing to buy or short SEO shares - or even before they post about them on a BB !!

Ok, so they are 9 months into the contract and yet to start in earnest? Does not sound as though they are going to deliver the 200?

tony, once again confusion reigns at seo . this is from the egm statement dated 30/8

"GREENSEALTM



Commercial trials with ASDA Stores Limited ('ASDA') suppliers have been
successfully completed and the 12 month exclusivity period with ASDA, who have
committed to converting several hundred machines in the period, commenced on
28th July 2005. To date, two contracts orders have been received from dedicated
ASDA suppliers covering 5 machines in total."

if you are right , then the situation is a damn sight worse than i previously thought.

BOS
Agreed - confusion indeed.

I would say more than confusion.....

IF the date is NOT 28th July 2005 as stated in that RNS then I believe that SEO have lied to both the market and investors. Clarification on this is required by SEO.

Apologies - I know this is of topic - but some may be interested. By the way - this is the sort of RNS I expected from SEO

BioProgress plc

BioProgress plc ('BioProgress', the 'Company' or 'Group') announces
Acquisition, Joint Venture, Fundraising and Trading Update

March, Cambridgeshire, 21 December 2005: The Board of BioProgress plc (AIM:
BPRG; NASDAQ: BPRG), the provider of innovative delivery mechanisms for the
pharmaceutical and medical device markets, is pleased to announce that it has
entered into an agreement to acquire the whole issued share capital of Dexo
S.A. ('Dexo'), a French speciality pharmaceutical company. This acquisition,
through a newly formed vehicle Dexo BioPharm Ltd ('Dexo BioPharm'), signals a
significant change from a drug delivery and material sciences company into an
integrated speciality pharmaceutical and healthcare business, which can develop
and market its core technologies in combination with other innovative products.

The consideration for the acquisition of Dexo is 12.5m, 8m of which will be
paid in cash and 4.5m in sterling denominated ordinary shares, representing
5,866,791 new ordinary shares (the 'Consideration Shares'), to be issued at the
time of completion. 2,607,463 Consideration Shares will be held in escrow as
security for the warranties given pursuant to the agreement. The holders of the
Consideration Shares will undertake on completion of the acquisition that they
will not transfer or dispose of any Consideration Shares until the date falling
1 month from the date of completion of the agreement; that they will not
transfer or dispose more than 1,303,731 Consideration Shares prior to the date
falling 12 months from the date of completion of the agreement; and that they
will not transfer or dispose more than an additional 1,303,731 Consideration
Shares prior to the date falling 36 months from the date of completion of the
agreement. The Consideration Shares will also be subject to an orderly market
agreement. It is expected that the completion of the acquisition will take
place on 5 January 2006.

The Consideration Shares represent approximately 4.77 per cent. of the issued
share capital of the Company and will rank pari passu in all respects with the
existing ordinary shares of the Group.

Dexo is a long standing profitable private company with specific expertise in
registering and marketing innovative branded products into the French
healthcare system. It operates in the area of registered pharmaceuticals, and
specialises in medicines to treat gastrointestinal illness, and products for
ear, nose and throat ailments, along with a treatment for Wilson's Disease (a
fatal disorder caused by excessive copper accumulation in the liver and brain,
affecting one in 30,000 people world wide). Dexo is currently run by Mr
Jean-Francois Sfarti, the former CEO of Sanofi Pharma France who will remain as
president of Dexo, along with the current team, running the operations in
France. To assist the current Dexo team and to coordinate the Group's
reorganisation and expansion into new markets, BioProgress has recruited
additional management experienced in the pharmaceutical field, including a
practising pharmacist to act as the Company's responsible pharmacist, and a
medical consultant.

For the year ended 31 December 2005, Dexo is expected to generate turnover of
approximately 6.5 million (2004: 6.2 million) with normalised net margins
above 30 per cent. Net assets of Dexo at completion are expected to be around
3.0 million.

Through the creation of the new pharmaceutical division BioProgress will be
able to apply its technologies to Dexo's products, develop new products and
market the enhanced products directly. This capability is expected to
demonstrate to consumers and partners the benefits of its technologies such as
XGEL. The new Dexo BioPharm division will be immediately accretive in cash
terms and creates the potential for near-term Group profitability.

Richard Trevillion, CEO of BioProgress, said: 'I am delighted to welcome the
management and staff of Dexo into the BioProgress group. Our technology lends
itself to rapid brand differentiation and improvement, particularly in areas of
patient compliance and product life cycle extension. With France's well known
history of accepting innovative pharmaceutical formulations, we see this as a
significant springboard to see maximum value for our company's technologies.'

Jean-Francois Sfarti said: 'Dexo is very pleased to be joining BioProgress.
BioProgress' platform technologies will allow us to add significant value to
our existing range of products and will enable us to access new product areas
with significantly improved product profiles and differentiation.'

The Group also today announces a new joint venture, fundraising and trading
update:

Joint Venture with Crescent Pharma

In parallel with the above acquisition, BioProgress has, through its
newly-formed pharmaceutical division Dexo BioPharm, entered into a joint
venture (JV) named Dexo BioGenerics Limited which is 75.1% owned by the Group.
The JV partner is a private generics supplier, Crescent Pharma Limited, part of
the General Mediterranean Group based in Basingstoke, which supplies a wide
range of generic and OTC medicines in the UK. This JV brings significant new
skill sets to the Group including manufacturing and regulatory know-how and a
wide range of product licences for generic medicines including NSAIDs,
simvastatin and diazepam. These will be combined with the Group's core oral
delivery technologies for rapid commercialisation.

There is no consideration payable on the formation of the JV. The development
and marketing of enhanced generics will be funded by Dexo BioPharma and the JV.
Marketing and administrative resources will be provided to the JV by Crescent
and the BioProgress Group.

Richard Trevillion, CEO of BioProgress, said: 'The combination of the JV with
the acquisition of Dexo S.A. brings to the Group instant cross border business
reach in two distinct markets, those of branded medicines and generic products.
The acquisition and JV are significant steps for the Company, changing its
overall structure into a focused integrated speciality healthcare business with
multiple revenue streams and solid partnerships.'

Mr Mohammed Al-Doori, Chief Executive of Crescent Pharma Limited, said: 'Dexo
BioGenerics, a joint venture between Dexo Biopharm and Crescent, will offer
patients an exciting new range of medicines by combining Crescent's range of
well established generic drugs with BioProgress' cutting edge delivery
technology. Crescent's market experience will assist in ensuring the commercial
success of the new product range.'

Fundraising

The Company also announces today the placing of 12,285,328 new ordinary shares
of 1p each with institutional and other investors (the 'New Ordinary Shares'),
representing approximately 9.99% of the current issued share capital of the
Company, at 47p per New Ordinary Share (representing a 12% discount to the
volume-weighted average share price as on 19 December 2005), under the
provisions of s.95 of the Company's Act 1985 as amended.

It is intended that the proceeds from the fundraising will be used to refinance
the cash consideration for the acquisition of Dexo and to provide additional
working capital for the Company, although the acquisition of Dexo by the
Company is not conditional on the fundraising.

The New Ordinary Shares will rank pari passu in all respects with the existing
ordinary shares of the Group. It is expected that admission to trading and
dealings in the New Ordinary Shares will commence on 3 January 2006.

Trading Update

Finally, the Board is also pleased to announce a positive organic trading and
development outlook and an expectation of near term growth. Due to the rapid
restructuring initiatives undertaken since the appointment of the new
management team in May of this year, the Group is in an improved financial
position with cash burn reduced by over 75% on an operational basis in line
with the comments made in the interim statement.

All key partnerships have also either been renegotiated or are being
renegotiated and the Company is in late stage discussions with a number of top
10 pharmaceutical companies for new commercialisation initiatives across its
range of technologies. Feasibility programmes are taking place across the
ingestible and non-ingestible product range with new partners, emphasising
BioProgress' rapid commercialisation solutions. In addition, the Company has
entered into evaluation contracts with a number of large pharmaceutical
companies.

As a consequence of restructuring and refocusing at BioProgress, the Group's
film production division BioTec Films is now producing a monthly net profit,
and the division's client list has been expanded. Measured investment is now
being undertaken to add to BioTec Films' offering and to link in and support
other new initiatives across the Group.

As part of the cost reduction initiatives and to reflect the changes to the
Group's structure, the Company will also be moving its premises from March to
the Cambridge Science Park during the first quarter. The move will decrease
rental lease costs by over 70% and locate the Group in an area renowned for
innovation in related industries. The Company has also established a London
presence to provide greater access to potential and existing partners and
advisors in addition to housing its new Dexo BioPharm division.

The Company also announces that it has settled legal proceedings brought
against it and some of its subsidiaries by a former employee of one of its US
subsidiaries. These proceedings were mentioned in the company's United States
20-F filing on page 43. The terms of the settlement are confidential.

This is taken from a RNS released on, 28/07/05, showing that the trials were completed on this date and from this date the 12 months exclusivity deal commenced.

Stanelco, the radio frequency (RF) company, is pleased to announce the stability
results of the third and final commercial trial with a third supplier to ASDA
have been received. The results showed that Stanelco's GREENSEAL technology
performed consistently better than the current heat sealing methodology during
the trial. This now concludes the trialling requirements under Stanelco's
contract with ASDA. The 12 month exclusivity period with ASDA has therefore now formally commenced and the roll out of GREENSEAL technology under the terms of
the contract will follow.

So we are about 5 months into the deal, not 9 months. The official trial period commenced in March of this year.

I fully agree as stated before SEO do confuse the issue by not being direct, IE they could just as easliy state ...Start of the 12 months, 28/07/05 finish 28/07/06.

just to muddy the waters further, there was this rns on 23rd may.....

"Stanelco PLC
23 May 2005

23 May 2005


Stanelco plc

Stanelco signs first Commercial Agreement with ASDA Supplier for GREENSEAL(TM)


Stanelco announces that following extensive trials it has now entered into a
formal commercial agreement for its GREENSEAL(TM) technology with a dedicated
ASDA supplier, endorsed by ASDA themselves. This first commercial agreement will
involve the conversion of a Mondini tray-lidding machine at the chosen supplier.
Stanelco cannot reveal the name of the supplier for commercially sensitive
reasons."

BPRG will be back to the placing price or lower in 6 months time, so I won't be rushing in like the other fools.

187

You seem to be forgetten that the BPRG placing is not for cashburn purposes but for a profit making aquisition, price will not pullback as the market see's it as a very positive step forward for Bioprogress.

The fact their also in talks with several top 10 pharma's and also that they've announced a new joint venture today just adds to the great news, thats before we even get to Biotec now being a profit making venture!

Keep your bitterness to yourself mate as this is not football team supporting, instead of treating Bioprogress as a rival treat them as a great investment oportunity.

ps If Balchin kept news till it was certain like RT at Bioprogress then Stanelco would be a lot better off.

BPRG ARE THE BOYS UP 10%

BUY , BUY,

bye bye SEO

rotfflmfao!!!!!!!!!

10p sooon!!!!!!!!!